NextCure (NASDAQ:NXTC) Stock Price Down 6.2% – Here’s Why
by Renee Jackson · The Cerbat GemNextCure, Inc. (NASDAQ:NXTC – Get Free Report) shares were down 6.2% during mid-day trading on Tuesday . The stock traded as low as $10.71 and last traded at $10.97. Approximately 96,252 shares were traded during trading, an increase of 71% from the average daily volume of 56,445 shares. The stock had previously closed at $11.70.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research note on Wednesday, January 28th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.00.
Get Our Latest Research Report on NextCure
NextCure Stock Performance
The firm has a market capitalization of $44.14 million, a price-to-earnings ratio of -0.62 and a beta of 1.57. The business’s 50 day moving average is $11.88 and its 200-day moving average is $11.47.
NextCure (NASDAQ:NXTC – Get Free Report) last posted its earnings results on Thursday, March 5th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $1.45. Equities research analysts forecast that NextCure, Inc. will post -8.21 EPS for the current fiscal year.
Institutional Investors Weigh In On NextCure
Hedge funds and other institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new stake in NextCure in the 4th quarter valued at about $3,382,000. Squadron Capital Management LLC acquired a new position in shares of NextCure during the fourth quarter worth approximately $3,363,000. Exome Asset Management LLC acquired a new position in shares of NextCure during the fourth quarter worth approximately $2,341,000. AWM Investment Company Inc. bought a new stake in shares of NextCure during the fourth quarter valued at approximately $1,665,000. Finally, Cable Car Capital LP grew its stake in shares of NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the last quarter. 42.65% of the stock is owned by institutional investors and hedge funds.
About NextCure
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.